Arkin Holdings
Arkin Holdings is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Arkin Holdings.
Arkin Holdings is a company.
Key people at Arkin Holdings.
Arkin Holdings is an Israeli multi-asset investment firm managing over $2 billion in assets, with a primary focus on healthcare and life sciences, alongside real estate and equities[1][3][4][6]. Founded by entrepreneur Mori Arkin, it invests across stages from seed onward, particularly in health tech, supporting startups in medical and developer platforms through its expertise in the pharmaceutical sector[1][2][5]. Its mission stems from Arkin's background building and selling a global pharma company for over $800 million, aiming to propel portfolio companies globally with a hands-on approach[1]. Key sectors include healthcare innovation, where it has a strong track record of exits, often co-investing with firms like Pontifax and Accelmed in rounds of $10-50 million[2].
The firm influences Israel's startup ecosystem as one of its largest private healthcare investors, backing early-stage companies (typically 2-3 or 8 years old at investment) with average valuations around $74 million, and achieving exits more frequently than peers (60 percentage points higher)[2][6].
Arkin Holdings traces its roots to 2009-2010, when Mori Arkin, a seasoned entrepreneur who built and sold a global pharmaceutical company for over $800 million in 2005, established the firm to leverage his life sciences expertise[1][2][4]. Headquartered in Herzliya Pituach, Israel, it began with a focus on health investments, evolving into a multi-asset manager overseeing health tech, real estate, and equities[1][3][4]. Key evolution includes shifting from pure life sciences to broader healthcare and tech, with notable activity peaking in 2016 and exits in 2015; it typically participates in fewer than 2 deals per year but leads less often than average while prioritizing high-exit potential[2].
Pivotal moments include early investments in startups like Quiet Therapeutics, Metabomed, and cCAM Biotherapeutics, often alongside Israeli government bodies and global players like Pfizer, solidifying its role in Israel's innovation hub[2].
Arkin Holdings rides the wave of Israel's health tech boom, capitalizing on the nation's strengths in medical innovation and developer platforms amid global demand for biotech solutions[2]. Timing aligns with post-2009 growth in life sciences funding, where market forces like aging populations and digital health advancements favor its expertise[1][6]. It influences the ecosystem by funding early traction (e.g., 2-3 year-old startups) and enabling exits, often with OCS and international partners, boosting Israel's position as a healthcare innovation hub[2]. This targeted approach amplifies local talent, bridging Israeli R&D with global scaling needs[1][4].
Arkin Holdings is poised to expand its $2B+ portfolio amid rising health tech investments, potentially deepening multi-asset diversification into AI-driven biotech and real estate synergies[3]. Trends like personalized medicine and Israeli tech exports will shape its path, with its high-exit model likely driving more unicorns from seed stages[2][5]. Influence may evolve toward greater operating partnerships, solidifying its role as a cornerstone for global healthcare scaling from Israel—echoing its founding spirit of turning expertise into worldwide success[1].
Key people at Arkin Holdings.
